



HK TIME	TITLE OF PRESENTATION	SPEAKER	MODERATOR/SESSION CHAIR	TITLE OF PRESENTATION	SPEAKER	MODERATOR/SESSION CHAIR
	Level 7, Ballroom			Level 8, Shantung Room		
10:15 - 10:25	Welcome					
	Breast Cancer			Special ASCO Highlights		
10:25 - 10:37	Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).	<b>Prof. Kevin Kalinsky</b> <i>Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA</i>	<b>Dr. Roland Leung</b> <i>Honorary Clinical Associate Professor in Medical Oncology, HKU Med</i>	Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.	<b>Prof. Michael Wang</b> <i>Professor, Department of Lymphoma &amp; Myeloma, MD Anderson</i>	Scientific Committee
10:37 - 10:45	Panel Discussion			Panel Discussion		
10:45 - 10:57	A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.	<b>Prof. Conte Pierfranco</b> <i>Scientific Directorate and Research Services San Camillo Hospital, IRCCS Veneia</i>		Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BpD) vs pomalidomide plus bortezomib and dexamethasone (PvD) in relapsed/refractory multiple myeloma (RRMM).	<b>Dr Raymond Wong</b> <i>Consultant in the Department of Medicine &amp; Therapeutics, Prince of Wales Hospital</i>	
10:57 - 11:05	Panel Discussion			Panel Discussion		
11:05 - 11:17	A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY Trial.	<b>Prof. Joohyuk Sohn</b> <i>Chairperson of Breast Cancer Committee, Korean Cancer Study Group, Seoul, Korea</i>		Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.	<b>Prof. Ang Mei Kim</b> <i>Senior Consultant and Head of Lung, Head and Neck and Genitourinary Oncology Service, Division of Medical Oncology, National Cancer Centre Singapore</i>	
11:17 - 11:25	Panel Discussion			Panel Discussion		
11:25 - 11:37	Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).	<b>Dr. Roland Leung</b> <i>Honorary Clinical Associate Professor in Medical Oncology, HKU Med</i>		Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.	<b>Prof. Aya El Helali</b> <i>President, The Hong Kong Neuro-oncology Society</i>	
11:37 - 11:45	Panel Discussion					
	Lung Cancer			Urological Cancer		
11:45 - 11:57	Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.	<b>Dr. Johnny Lau</b> <i>Honorary Clinical Assistant Professor, University of Hong Kong</i>	<b>Prof. Roger Ngan</b> <i>Honorary Consultant in Clinical Oncology, Gleneagles Hospital</i>	Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore)	<b>Prof. Michael J. Morris</b> <i>MD, Prostate Cancer Section Head, Memorial Sloan Kettering Cancer Center, New York</i>	<b>Dr. Darren Poon</b> <i>Associate Director, Comprehensive Oncology Centre, Hong Kong Sanatorium Hospital</i>
11:57 - 12:05	Panel Discussion			Panel Discussion		
12:05 - 12:17	ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).	<b>Prof. Matthew Chiu</b> <i>Department of Clinical Oncology, University of Hong Kong</i>		A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).	<b>Prof. Michael J. Morris</b> <i>MD, Prostate Cancer Section Head, Memorial Sloan Kettering Cancer Center, New York</i>	
12:17 - 12:25	Panel Discussion			Panel Discussion		
12:25 - 12:37	Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.	<b>Dr. Choy Tim Shing</b> <i>Head of Clinical Oncology at The Hong Kong Integrated Oncology Center</i>		Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial.	<b>Dr. Darren Poon</b> <i>Associate Director, Comprehensive Oncology Centre, Hong Kong Sanatorium Hospital</i>	
12:37 - 12:45	Panel Discussion		Panel Discussion			

12:45 - 13:45	<b>LUNCH</b>					
	<b>Main Plenary</b>					
13:45 - 14:00	Adjuvant Osimertinib after radical CRT for inoperable stage 3 NSCLC (LAURA Study)	<b>Prof. Liu Hui</b> <i>Chief Physician, Professor, Deputy Director of Radiation Oncology Department, Sun Yat-sen University Cancer Center</i>	<b>Dr. Peter Teo</b> <i>Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium Hospital</i>			
14:00 - 14:10	<b>Panel Discussion</b>					
14:10 - 14:25	Perioperative FLOT chemotherapy for resectable node-positive and/or cT2 or higher T-stage adenocarcinoma of esophagus compared to preoperative chemoradiation for PFS in OESOPEC Study	<b>Dr. Peter Teo</b> <i>Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium Hospital</i>				
14:25 - 14:35	<b>Panel Discussion</b>					
	<b>Gastrointestinal &amp; Liver Cancer</b>			<b>Gynecological Cancer</b>		
14:35 - 14:47	Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator's choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).	<b>Dr. Jeffrey Wong</b> <i>Medical Oncology, Queen Mary Hospital</i>	<b>Prof. George Lau</b> <i>Chairman and Senior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Group, HKSAR, China</i>	Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/ GOG-0724.	<b>Dr. Anuja Jhingran</b> <i>Professor, Department of Radiation Oncology University of Texas MD Anderson Cancer Center</i>	<b>Prof. KY Tse</b> <i>Clinical Associate Professor in the Department of Obstetrics and Gynaecology at The University of Hong Kong</i>
14:47 - 14:55	<b>Panel Discussion</b>			<b>Panel Discussion</b>		
14:55 - 15:07	Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW.	<b>Prof. George Lau</b> <i>Chairman and Senior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Group, HKSAR, China</i>		Final Results of BRUOG354: A Randomized Phase II Trial of Nivolumab alone or in combination with Ipilimumab for People with Ovarian and other Extrarenal Clear Cell Carcinomas	<b>Prof. Roger Ngan</b> <i>Honorary Consultant in Clinical Oncology, Gleneagles Hospital</i>	
15:07 - 15:15	<b>Panel Discussion</b>		<b>Panel Discussion</b>			
15:15 - 15:45	Gastrointestinal Cancer Highlight Session Immune Checkpoint Inhibitors in Metastatic MSI-H/ dMMR CRC in 2024 - 3 (CheckMate 8HW study)	<b>Prof. Thierry André</b> <i>Professor of Medical Oncology, Sorbonne Université in Paris and Head of the Medical Oncology Department at the Saint Antoine Hospital, Assistance Publique Hôpitaux de Paris, France</i>	<b>Dr. Peter Teo</b> <i>Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium Hospital</i>	<b>Live Session is conducted at Level 7 Ballroom</b>		
15:45 - 16:00	<b>Panel Discussion</b>		<b>Panel Discussion</b>			
16:00 - 16:12	Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.	<b>Prof. Shuichiro Shiina, MD, PHD</b> <i>Department of Gastroenterology, Jutendo University</i>	<b>Prof. George Lau</b> <i>Chairman and Senior Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Group, HKSAR, China</i>	Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.	<b>Prof. Karen Chan</b> <i>Department Chairperson and Clinical Professor, HKU Med</i>	<b>Prof. KY Tse</b> <i>Clinical Associate Professor in the Department of Obstetrics and Gynaecology at The University of Hong Kong</i>
16:12 - 16:20	<b>Panel Discussion</b>			<b>Panel Discussion</b>		
16:20 - 16:32	Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET).	<b>Prof. Ronnie Poon</b> <i>Honorary Consultant in General Surgery, Gleneagles Hospital</i>		Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).	<b>Dr. Wu Philip Yuguang</b> <i>Specialist in Clinical Oncology</i>	
16:32 - 16:40	<b>Panel Discussion</b>		<b>Panel Discussion</b>			
16:40 - 17:00	<b>VALEDICTORY &amp; THANK YOU</b>					